Goldman Sachs: Maintains "Neutral" rating on LONKING (03339) with a target price of 1.6 Hong Kong dollars.
Goldman Sachs maintains a cautious attitude towards the demand cycle for construction machinery in mainland China.
Goldman Sachs released a research report stating that based on the latest sales trends of LONKING (03339)'s main products, it has made a slight adjustment of 0-2% to the earnings per share for 2024-26, and maintained the stock's target price at 1.6 Hong Kong dollars with a "neutral" rating.
The report points out that a cautious attitude is held towards the demand cycle for construction machinery in Mainland China. Within the coverage of construction machinery in Mainland China by the bank, it believes that LONKING is in the most unfavorable position. This is due to the consolidation of the wheeled loader market in Mainland China, indicating minimal growth potential for market share, structural losses in market share for excavators, limited export potential, and weakness in the domestic market for earthmoving machinery.
The bank believes that all negative factors seem to have already been factored in, and demand for wheeled loaders in Mainland China seems to have normalized to the global average level outside of China by 2023 compared to demand for excavators.
Related Articles

Zions Bancorporation, N.A. (ZION.US) Q3 profits exceed expectations Analyst: Credit pressure for banks in the U.S. region still remains an isolated issue.

GUOTAI JUNAN I: Why are gold and US Treasury bonds rising together amid the frenzy of "depreciation trading" in the US dollar?

SINO BIOPHARM (01177): The study data of the first-line treatment of advanced stage III breast cancer with the combination of Comorsi and Fluvisq was announced at ESMO 2025.
Zions Bancorporation, N.A. (ZION.US) Q3 profits exceed expectations Analyst: Credit pressure for banks in the U.S. region still remains an isolated issue.

GUOTAI JUNAN I: Why are gold and US Treasury bonds rising together amid the frenzy of "depreciation trading" in the US dollar?

SINO BIOPHARM (01177): The study data of the first-line treatment of advanced stage III breast cancer with the combination of Comorsi and Fluvisq was announced at ESMO 2025.

RECOMMEND

Why European Automakers Are Opposing Dutch Sanctions
20/10/2025

Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025

Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025